Patent applications published 2 June 2010

Published: 15-Jul-2010
Patient Experience

Selected patent applications from the weekly European Patents Bulletin


  • HSP90 inhibitors with modified toxicity
    The Regents of the University of Colorado 2190291*

  • Oestrogenic extracts of Scuttelaria barbata D Don of the Labiatae family and uses thereof
    Bionovo 2190292*

  • Compounds and methods for treating zinc matrix metalloprotease dependent diseases
    Absolute Science 2190293*

  • Cyclosporin compsns
    Allergan 2190407*

  • Analgesic and anti-inflammatory compsns and methods for reducing, preventing or treating pain and inflammation
    Medtronic; Warsaw Orthopaedic 2190408*

  • Delivery of drug combinations
    Biocompatibles UK 2190409*

  • Use of carbon nanotubes for drug delivery
    Ensyce Biosciences 2190410*

  • Liposome compsns for in vivo administration of boronic acid compounds
    Alza Corp 2190411*

  • Liposome formulations of boronic acid compounds
    Alza Corp 2190412*

  • Compsns for the treatment of neoplastic diseases
    Vereniging Het Nederlands Kanker Instituut; Slotervaart Participaties 2190413*

  • Method for stabilising phenylephrine
    McNeil-PPC 2190415*

  • Pharmaceutical compsns of fenofibrate
    Wockhardt Research Centre 2190415*

  • Method and compsn for making an orally disintegrating dosage form
    McNeil-PPC 2190416*

  • Pharmaceutical compsns comprising insulin sensitiser and insulin secretagogue
    Teva Pharmaceutical Industries 2190417*

  • Immediate release and sustained release ibuprofen dosing regiment
    McNeil-PPC 2190418*

  • Multi-particulate matrix system containing galantamine
    KRKA 2190419*

  • Gelatin-based coatings having improved durability
    McNeil-PPC 2190420*

  • 17-beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases
    Universität des Saarlandes 2190421*

  • A method of extending the dose range of vitamin D compounds
    Wisconsin Alumni Research Foundation 2190422*

  • Arabinoxylo-oligosaccharides useful against gastrointestinal infections
    Fugeia 2190423*

  • Use of a monoterpene to increase tissue repair
    Aisa Therapeutics 2190424*

  • Topically applicable fungicide agents for treating nails
    BioEqual 2190425*

  • Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
    DKFZ Deutsches Krebsforschungs-zentrum; Technical University of Denmark 2190426*

  • Use of tocopherol derivatives as inhibitors of the notch signalling pathway
    INSERM (Institut National de la Santé et de la Recherche Médicale) 2190427*

  • Heterocyclic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
    Merck Sharp & Dohme 2190428*

  • A novel group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors
    Boston Biomedical 2190429*

  • Use of compounds derived from cyclo-heximide for the treatment or prevention of, in particular, ischaemias and cardiopathies
    Max-Planck-Gesellschaft zur Förderung der Wissenschaften 2190430*

  • Compsns comprising a dissociated glucocorticoid receptor agonist for treating or controlling anterior-segment inflammation
    Bausch & Lomb 2190431*

  • Pyrimidine and pyridine derivatives as POSH and POSH-AP inhibitors
    Protelogics 2190432*

  • Therapy for complications of diabetes
    Gilead Colorado 2190433*

  • Purin derivatives for use in the treatment of FAB-related diseases
    Boehringer Ingelheim International 2190434*

  • Treatment of sleep disorders
    Evotec Neurosciences 2190435*

  • Sulfasalazine formulations in a biodegradable polymer carrier
    Warsaw Orthopaedic; Medtronic 2190436*

  • Use of vitamin B12 for treatment of mucosal lesions
    Rudoy, Inna; Volkov, Illia; Press, Yan; Eldal, Michal 2190437*

  • Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
    Nestec 2190438*

  • Synthesis of oseltamivir containing phosphonate congeners with anti-influenza activity
    Academia Sinica 2190439*

  • Combination motif immune stimulatory oligonucleotides with improved activity
    Pfizer; Coley Pharmaceutical Group; Coley Pharmaceutical GmbH 2190440*

  • Polymers with bio-functional self-assembling monolayer endgroups for therapeutic applications and blood filtration
    DSM 2190441*

  • An apparatus and method for treatment and prevention of infectious disease
    Ortho-Ion 2190442*

  • Pharmaceutical compsn for preventing and treating cell proliferative disease comprising mixture of feather of birds and scale of fish as an active ingredient
    Lee, Sang Moon 2190444*

  • Use of stresscopin-related peptide as a therapeutic agent
    Mondobiotech Laboratories 2190447*

  • Methods and uses thereof of prosaposin
    Children’s Medical Centre Corp 2190448*

  • Macrocyclic compounds and methods of treatment
    University of Florida Research Foundation 2190449*

  • Use of melanin-concentrating hormone and MET-enkephalin as therapeutic agents
    Mondobiotech Laboratories 2190450*

  • Treatment of atherosclerosis
    Affris 2190451*

  • Use of a peptide as a therapeutic agent
    Mondobiotech Laboratories 2190452*

  • Use of TRP6-troptirelin and D-leu6-leuprolide as therapeutic agents
    Mondobiotech Laboratories 2190453*

  • Delivery systems for solubilising water-insoluble pharmaceutical active ingredients
    EMS SA 2190454*

See more

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

Read more
The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape

Trending Articles

  1. Pfizer wins battle over Viagra trademark Energy drinks brand Viaguara cannot be registered as an EU trademark
  2. Patent applications published 7 July 2010 Selected patent applications from the weekly European Patents Bulletin
  3. Genmab says GSK has settled patent case with Genentech Concerning two US patents for ofatumumbab
  4. Boehringer Ingelheim suffers Spiriva patent blow in India Indian patent office has revoked a patent granted for tiotropium bromide monohydrate under the Spiriva brand, paving the way for Cipla to continue selling its generic version in the Indian market
  5. Phillips-Medisize acquires mini-tablet dispenser patent The US company has acquired exclusive ownership of the patent from a global pharmaceutical company and expects to make the product available by early 2020

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape
Regulatory

Pharmaseal reaches milestone in crowdfunding campaign

The company was first founded in 2016
Patient Experience

Ilya Pharma awarded engineered lactic acid bacterial strain patent

The patent covers the use of engineered lactic acid bacterial strains for all human and animal wounds, not just skin
Pharmaceutical

A card in the competition for COVID-19 drug supply

The patent system has come under pressure both politically and, more recently, as pharma companies scale-up their operations to make large amounts of drugs available to treat COVID-19, reports Paul England, Senior Professional Support Lawyer at Taylor Wessing
Ingredients

Sigrid Therapeutics obtains US patent for silica-based biomaterial SiPore15 for the treatment and prevention of obesity

Mesoporous silica particles (MSP) are a type of ingestible synthetic amorphous silica particles that can be produced with a large surface area and a range of pore sizes
Ingredients

VistaGen and Nuformix agree to develop cocrystalline forms of AV-101

The drug for treatment of multiple CNS conditions will be reformed into a novel patentable form to potentially improve delivery and give more intellectual property protection
Digital

Documentation complexity at crisis point?

Do we focus too much on the paperwork, to the detriment of product and patients? Has documentation become so complex it’s become a dangerous distraction and your biggest risk? by Martin Lush
Subscribe now